Moderna's Post-IPO Losses Deepen After Cancer Conference, Lockup

(Bloomberg) -- Moderna Inc. shares sank as much as 12% for their biggest intraday drop since the biotech’s first day of trading in December.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.